At Quibim, we design pioneering tools that unlock imaging data to improve patient outcomes. Our main purpose is the application of AI techniques to medical images from MRI, CT, PET to unlock new data which can be transformed into actionable predictions for life sciences and providers.

Horizon 2020

EASME - EU Executive Agency for SMEs

Angels Capital

Tech Transfer UPV

Crista Galli Ventures

Partech

Adara Ventures

Amadeus Capital Partners

APEX Ventures

Quibim

🔴 Did you miss our latest webinar? If you skipped our latest conversation on the intersection of #AI and radiomics in biopharma, don't worry! The recording is now available so you can catch up on all the discussions and innovative ideas shared by our top-notch speakers.
 
💻  Ideal for researchers, scientists, and professionals in the biopharmaceutical, technology, and medical fields looking to stay current in this rapidly changing landscape, the transformative impact of AI was highlighted through case studies and success stories shared by our panel of experts.

Take advantage of this chance to access the valuable insights shared during the live event! https://bit.ly/47S8v6b 

Pamod Hemakumara
Fuensanta Bellvís Bataller
Ronald Korn

❄ We recently attended the 'Journées d'Hiver de la Société d'Imagerie Génito-Urinaire (SIGU) 2024', organized by the Société Française de Radiologie et d'imagerie médicale (SFR).

It was amazing to interact with the French Genito-Urinary Imaging Society, exchanging views, and collaborating with subject matter experts, we showcased our cutting-edge imaging and #prostate solutions.

Special thanks to Philippe PUECH, Raphaële Renard Penna , carole delerue and Patricia Gutierrez for their organization. Stay tuned for updates from this event in the heart of the French Alps!

#MedicalImaging #PrecisionHealth

Exciting news! We are proud to announce our strategic collaboration with Merck KGaA, Darmstadt, Germany to advance #PrecisionMedicine through AI-powered radiomics solutions.

🌍 Global challenge: Efficient clinical development for #cancer is a critical challenge globally, given the increasing number of patients needing personalized treatment. According to the Global Cancer Observatory, with cancer cases expected to reach 30 million new cases each year by 2040, our mission is to reduce costs and timelines in drug development programs.
 
🎯 Precise solution: Our #AI expertise creates predictive models, optimizing patient stratification and characterization and understanding the potential benefits of novel therapies. Merck intends to integrate these models into its global drug development and commercialization strategies, fostering #data-driven decision-making.
 
Read everything about it https://bit.ly/3OioIdQ and stay tuned for updates as we further transform #cancercare.

🚀 At the vanguard of innovation our CEO, Dr.Ángel Alberich-Bayarri, participated this morning in the latest #TechTrends 2024, organized by Globant and Business Insider España. The conference has delved into fundamental and relevant topics such as #AI or quantum computing, areas that are changing industries and driving transformational changes.
 
Discussions like this truly underscore our commitment to staying ahead of the curve, embracing emerging technologies and contributing to the global dialogue on #innovation. It was a great opportunity to network with thought leaders, industry experts and visionaries conducting change in the technology landscape.

Quibim is a company that designs pioneering tools to unlock imaging data and improve patient outcomes. They apply AI techniques to medical images from MRI, CT, PET to create actionable predictions for life sciences and providers.

COM:QUIBIM

Quibim

Filings Not Available